NEW YORK (GenomeWeb News) – Celera said today that it has signed an exclusive, two-year licensing deal with Merck, under which the pharmaceutical giant will have access to up to 10 cancer targets discovered by Celera using its proteomics discovery platform.
The Alameda, Calif.-based subsidiary of Applera said that Merck would use the targets to develop RNAi-based therapeutics.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.